IRCT20200329046892N3 IRCT 2021-03-29 Rasht University of Medical Sciences Effect of ivermectin in COVID-19 Study of Ivermectin Effectiveness in treatment process, survival and cure rate of COVID-19 patients: a randomized clinical trial 2021-04-09 anticipated 60 Complete https://irct.ir/trial/55216 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: It is a block randomization type and the block with size of 4. Randomization tool: sealedenvelope.com. 60 patients will be assigned in 15 blocks of 4. In intervention group (A) they will receive Ivermectin 12 mg/day (Four 3 mg Tablets) orally for 2 days + standard care for 10 days and in control group (B) they will receive (Four 3 mg Placebo tablets) orally for 2 days + standard care for 10 days. Concealment is done using the sealed envelope method, Blinding description: In this study, participants (patients) and medical staff are kept blind to the specificity of study groups (Double-blinded). For this purpose, an independent person from the research team and an Infectious Diseases specialist prescribes the assigned codes to each patient. Efforts will be made to make the drug and placebo by one company to ensure the similarity. Study drugs will be placed in similar packages, and patients will receive pre-arranged interventions in the order in which they enter the study. 2-3 Condition 1: COVID-19. Condition 2: COVID-19. Intervention 1: Intervention group: Ivermectin (Alborz-Daru) 12 mg/day (Four 3 mg Tablets) orally for 2 days + standard care for 10 days or hospital discharge (whichever comes first). Intervention 2: Control group: Four 3 mg Tablets orally for 2 days + standard care for 10 days or hospital discharge (whichever comes first). Yes - There is a plan to make this available What will be shared: Data about primary outcome When: 2 months after results published To whom: Researchers Conditions: Requested by authenticated scientific centers and universities Where to obtain: Dr. Nematollah Ahangar School of Medicine Email: n.ahangar@gums.ac.ir How to obtain: Official request signed by highest executive is mandatory. Moreover, acceptable reasons should be noted Comments: